NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
LESCOL XL (fluvastatin sodium) by Novartis is hmg-coa reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) to mevalonate, a precursor of cholesterol. First approved in 2000.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LESCOL XL is an oral extended-release tablet containing fluvastatin sodium, an HMG-CoA reductase inhibitor (statin) used to treat lipid metabolism disorders. It works by inhibiting the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and triglycerides. The drug has been approved since 2000 and remains a standard-of-care option for dyslipidemia management.
$0.722MPart D
LOE ApproachingDeclining
With LOE approaching and minimal Part D spending ($722K in 2023), LESCOL XL represents a mature, low-growth portfolio asset requiring defensive commercial strategies and reduced headcount.
Mechanism of Action
HMG-CoA reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of cholesterol.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Started Jan 2012
436 enrolled
Lipid Metabolism Disorders
Career Relevance
LESCOL XL currently shows zero linked job openings, reflecting its status as a mature, declining asset with minimal active commercial investment. Professionals considering careers tied to this product should expect limited growth opportunities, smaller team sizes, and focus on defensive market strategies rather than innovation or expansion.
Company
Worked on LESCOL XL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.